Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
For the comparison of adults who had claims for opioids vs claims for no opioids or PPM, the following variables were significant in the bivariate analysis (Tables S1 and S2): age and age group on the index date, geographic region, payer channel, CCI score, all the musculoskeletal conditions except kyphosis and scoliosis, all 3 non-musculoskeletal manifestations, “rickets,” vitamin D deficiency, dental complications, difficulty walking, muscle weakness, osteomalacia, claims for cholecalciferol, claims for PT or occupational therapy, and the number of PT visits.
Source: Adults. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Clinical characteristics of adult and pediatric patients were collected for the baseline period (the 12 mo preceding the index date) for patients who were continuously enrolled for medical and pharmacy benefits during that period.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Pain medication use in patients with X-linked hypophosphatemia treated with burosumab: a retrospective real-world study
Study design awaiting verification · JBMR Plus · 2026
Original publication title
Pain medication use in patients with X-linked hypophosphatemia treated with burosumab: a retrospective real-world study
© The Author(s) 2026. Published by Oxford University Press on behalf of the American Society for Bone and Mineral Research.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Abstract
X-linked hypophosphatemia (XLH) is a rare, progressive phosphate-wasting disorder that leads to significant skeletal morbidity and pain. The current study used real-world administrative claims data to assess the demographic and clinical characteristics of patients with XLH related to claims for prescription pain medication (PPM) during the 12 mo before starting burosumab treatment (baseline) and explores changes in PPM claims after starting burosumab treatment. Claims for XLH-related musculoskeletal and deformity-related conditions, obesity, and osteoarthritis were common among the adult cohort (n = 387).
Claims for PPM (vs no claims) during baseline were significantly (p < .05) associated with: age ≥ 50 yr (odds ratio [OR] 2.54), Medicaid coverage (2.25), myalgia (2.54), scoliosis (3.19), obesity (2.07), dental complications (2.53), and physical therapy (2.94). Approximately half of the adult cohort (54%) made PPM claims during baseline, and 38% for opioids, with little change after starting burosumab. Claims for arthralgia, hip/leg deformities and rickets were common in pediatric patients (n = 524). Claims for PPM were significantly associated with race (OR 0.13), chronic pulmonary disease (4.34), renal disease (4.88), arthralgia (2.20), cholecalciferol claims (1.93), and physical therapy (3.48).
About one-fifth of pediatric patients (25%) had claims for PPM prescriptions during baseline, with little change after 12 mo, but showed a modest decrease during the second year of follow-up; 12%-17% of pediatric patients had claims for opioids during baseline and follow-up. The number of days covered by opioid prescriptions was lower in pediatric patients than in adults. Multiple factors are associated with PPM use in patients with XLH. Understanding these factors may inform patient-centered pain management strategies. A longer study is needed to determine how burosumab treatment affects pain and the use of PPM in patients with XLH.
Authors’ abstract
Abstract
X-linked hypophosphatemia (XLH) is a rare, progressive phosphate-wasting disorder that leads to significant skeletal morbidity and pain. The current study used real-world administrative claims data to assess the demographic and clinical characteristics of patients with XLH related to claims for prescription pain medication (PPM) during the 12 mo before starting burosumab treatment (baseline) and explores changes in PPM claims after starting burosumab treatment. Claims for XLH-related musculoskeletal and deformity-related conditions, obesity, and osteoarthritis were common among the adult cohort (n = 387).
Claims for PPM (vs no claims) during baseline were significantly (p < .05) associated with: age ≥ 50 yr (odds ratio [OR] 2.54), Medicaid coverage (2.25), myalgia (2.54), scoliosis (3.19), obesity (2.07), dental complications (2.53), and physical therapy (2.94). Approximately half of the adult cohort (54%) made PPM claims during baseline, and 38% for opioids, with little change after starting burosumab. Claims for arthralgia, hip/leg deformities and rickets were common in pediatric patients (n = 524). Claims for PPM were significantly associated with race (OR 0.13), chronic pulmonary disease (4.34), renal disease (4.88), arthralgia (2.20), cholecalciferol claims (1.93), and physical therapy (3.48).
About one-fifth of pediatric patients (25%) had claims for PPM prescriptions during baseline, with little change after 12 mo, but showed a modest decrease during the second year of follow-up; 12%-17% of pediatric patients had claims for opioids during baseline and follow-up. The number of days covered by opioid prescriptions was lower in pediatric patients than in adults. Multiple factors are associated with PPM use in patients with XLH. Understanding these factors may inform patient-centered pain management strategies. A longer study is needed to determine how burosumab treatment affects pain and the use of PPM in patients with XLH.
Publication and source details
Original title: Pain medication use in patients with X-linked hypophosphatemia treated with burosumab: a retrospective real-world study
Carolyn M Macica; Zhiyi Li; Ben Johnson; Ahmed Noman; Catherine Park; Gina N Woods
JBMR Plus · 2026
Corresponding author: Carolyn M. Macica, Connecticut Children's Medical Center, Department of Research Operations and Development, 282 Washington St, Hartford, CT 06106, United States (CMacica@connecticutchildrens.org).© The Author(s) 2026. Published by Oxford University Press on behalf of the American Society for Bone and Mineral Research.2026https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. Kyowa Kirin10.13039/100016348Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-10T23:37:50.718034+00:00
DOI: 10.1093/jbmrpl/ziag047 · PMC13117624